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Biology in the postgenomic era will require individuals with new sets of skillswho can establish themselves successfully in rapidly moving fields of
research. Philanthropy has played and will continue to play an important part in
jump-starting the careers of new investigators, particularly during the transition
from postdoctoral fellow to faculty member, and in building bridges between
traditional and emerging fields of research. The receipt of funding from a
prestigious foundation, health agency, or medical research organization can be
the push that launches a research career. In addition, because the mission of
philanthropy is often problem based, private funds can support inherently
interdisciplinary research and training that breaks new ground. 
Although the magnitude of private contributions to biomedical research
training cannot match that of the federal government, philanthropy plays a
special role. Foundations can complement public programs to realize a sub-
stantial impact. In addition, they can support alliances that typically would not
be supported through public mechanisms. Private philanthropies, particularly
voluntary health agencies with a disease focus, can provide critical help to 
fill the gap between the rate of advance in research and the translation of 
new knowledge into therapies for human disease. Private funders can use 
their resources to encourage beginning investigators to enter a research area
critical to the agency’s mission or to encourage midcareer investigators to
change course in their area of research focus. 
We sponsored and convened this conference to explore in depth the unique
contribution private funders can make to ensure that appropriate and adequate
training programs are available for basic and clinical research. Two years ago,
in February 1998, we convened a successful first meeting on this topic and
subsequently determined that an ongoing dialogue in the private funding
community was a most useful step toward achieving an objective important to
all those invited—ensuring that future biomedical research questions can be
answered by a well-prepared cadre of basic and clinical scientists. 
We believe this gathering met our goals. Participants formed new relation-
ships with other private funders and considered new directions in which they
might take their own organizations. The conference reinforced our belief that
private funds can change the culture and structures of research and education,
not merely supplement the substantial investment made by the public sector.
Because some of the most exciting work of the postgenomic era will occur at
the interface of disciplines, private funders can provide the “glue” needed to
compel faculty to work together toward research and educational goals.
Importantly, the private sector can search for the right niche and experiment
with innovative approaches. 
This report summarizes the meeting and is intended to provide similar stimuli
for those who were unable to attend. It is our hope that the philanthropic
community will continue the many conversations that were initiated at this 
conference.
Thomas R. Cech, Ph.D.
President
Howard Hughes Medical Institute
Enriqueta C. Bond, Ph.D.
President
Burroughs Wellcome Fund
John Stevens, M.D.
Vice President for Extramural Grants
American Cancer Society
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1Executive
Summary
On February 14-16, 2000, the American Cancer Society, the BurroughsWellcome Fund, and the Howard Hughes Medical Institute convened
a meeting on private sector support for biomedical research training. The
goal of the meeting was to address the unique contribution that private 
funders can make in ensuring that appropriate and adequate training 
programs are available for basic and clinical research. Representatives from
government, academia, and nongovernmental funding agencies had the
opportunity to hear presentations and discuss current programs and plans
of public and private funders and to consider goals for the future.
The meeting focused on training two groups of future investigators: basic
biomedical and clinical scientists. In addition, cross-cutting topics were
addressed, such as the move toward electronic grantsmaking and ethical
issues facing future biomedical research. 
Conclusions and Recommendations for 
Training of Basic Biomedical Scientists
Out of the sessions on training basic biomedical scientists emerged the 
following conclusions and recommendations:
1. In the postgenomic era of research, multidisciplinary and interdis-
ciplinary research will command center stage, requiring team
approaches and the collaboration of many individuals from vastly differ-
ent fields, ranging from computational mathematics to clinical science.
22. The need for team approaches to scien-
tific research suggests that private fun-
ders can make a significant difference in
building expertise and collaborations by
providing support to clusters of faculty.
3. Support of postdoctoral students and
new faculty is important, but insufficient.
Philanthropy must also invest in the
development of scientists from under-
represented groups, provide appropri-
ate support for foreign students, and
recognize that with the globalization of
the research enterprise, it will be vital to
provide experiences for U.S. students
abroad.
4. The changing paradigm of research calls
for innovations and changes in the edu-
cation of scientists along the spectrum 
of K-12, undergraduate, and graduate
education. The increasing need to value
teaching in all settings could be im-
proved by making grants that help 
free the time of scholar/researchers for
teaching. 
5. The private sector can facilitate some
areas or types of research more easily
than can public agencies. This would
include, for example, research with
embryonic stem cells or prehypothesis-
driven work to assemble and organize
information that can provide a platform
for hypothesis-driven work and infra-
structure support.
6. Partnerships among private funders
and between the public and private
sector will be valuable in moving the
postgenomic research and training
agenda forward and in leveraging the
investments of both private sector and
public sector groups.
Conclusions and 
Recommendations for 
Training of Clinical
Researchers
The genetic revolution and other scientific
advances are providing vast new and exciting
opportunities in clinical research. Investments
to advance the training of clinical researchers
were proposed in two major areas—human
capital and training programs. 
1. The development of clinical scientists 
is a good target for private support. As
with training basic scientists, it is 
critically important to support young 
clinical scientists, although other steps 
in the ladder also require attention.
Research experiences during medical
school, modeled after programs such 
as the Howard Hughes Medical Institute-
National Institutes of Health (NIH) 
Cloister Program and the NIH-Pfizer
Clinical Research Training Program, are
excellent examples of support of clini-
cal investigators early in their careers.
2. The M.D.-Ph.D. is the most successful
model for the development of clinical 
scientists. This paradigm should be 
supported by the private sector in order
to expand the numbers of trainees at
currently funded sites or to develop
new programs at institutions that could
then become eligible for NIH support.
3. Despite the predominance of the M.D.-
Ph.D. scientist, there are other essential
types of physician-scientists, and these
scientists require different types of 
support.
• Numerous new master’s-level pro-
grams are in development for clinical
research training. The private sector
can make a contribution by assisting
with tuition support.
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• Ph.D.s, if trained in pathobiology or
other human disease constructs, can
provide an invaluable resource to the
clinical research team.
4. Transition support to assist individuals at
key points in their training and career
development, such as between thesis
work and the first independent faculty
position, can be essential to prevent
young scientists from leaving research.
In this respect, debt relief is crucial.
5. The development of multidisciplinary 
and generic training programs in clini-
cal research is urgently needed, and 
the collaboration of disease-oriented
groups could make a critical difference.
Such a consortium could provide funds
for junior faculty and graduate students
as they make key education and career
transitions.
6. The private sector could support innov-
ative mechanisms by which to develop
and support mentorship skills in new
and existing faculty.
At the meeting’s end, several private 
funders agreed to pursue a joint project or 
collaboration in some specific area where
organizations share a need and desired 
outcome. Possible collaborations include 
1) pilot programs to enhance the supply 
of clinical investigators (Ph.D. or M.D.); 
2) institutional training programs that break
down departmental barriers and promote
new models for training; 3) loan repayment
programs to entice M.D.s to continue in re-
search; and 4) career development programs.
4Training Basic
Scientists for the
Postgenomic Era
In a field moving as rapidly as biomedical science, it is difficult to predict whichskills are required of today’s scientists, let alone those that will be necessary for
the next generation. A survey of the existing landscape, however, provides a
sense of the directions in which science is headed.
In his keynote speech, David Botstein, Professor and Chairman in the Depart-
ment of Genetics at Stanford University, provided a perspective that is both invig-
orating and demanding. In the new world of genomics, scientists are at the
beginning of a journey that will lead to the eventual understanding of every human
protein and its role both in health and disease. As the Human Genome Project
reaches completion—resulting in a complete map of the human genetic code—
the next challenge will be to identify the functions of the genes that have been
mapped, the proteins for which they code, and the functions of those proteins in
the body.
Such information will move the practice of medicine in the direction of pre-
vention and treatment based on molecular makeups. Initially, discovering how
health depends on single mutations (genotypic features) and single proteins
(phenotypic features) will be relatively straightforward. For example, it may in-
volve understanding how single nucleotide polymorphisms (SNPs) are related to
how cancers develop and ways in which we can diagnose disease and tailor
medications. With time, however, more intricate relationships likely will be 
discovered through population-based studies, entailing the generation, 
storage, and analysis of enormous quantities of epidemiologic, genotypic, and 
phenotypic data.
The immense amount of information generated by the Human Genome Project
is stimulating new collaborations between the traditional sciences of biology and
chemistry and the fields of bioinformatics, computer science, and mathematics. 
In the words of Botstein, “When you are work-
ing with 750 megabytes of biological informa-
tion, computational power is not optional, it is
necessary. Without a computer we cannot do
anything with the human genome.”
Botstein predicts that scientists will spend
the next 20 years figuring out the significance
and relationships of the human genome map.
To understand the similarities and differences
among organisms and between species,
sophisticated comparisons must be con-
ducted, and these comparisons cannot be
done by hand or by eye. Advanced bioinfor-
matics, combined with well-designed data-
bases and powerful computers, is providing a
view of the relationships among organisms
that are sometimes separated in evolution by
billions of years, and computers can display
patterns and periodicity that would never be
found if searched for manually. Said Botstein,
“Computers allow us to make discoveries on
which we can base beautiful hypotheses that
can then be tested.”
Molecular biologists and biochemists have
developed a variety of laboratory-based
assays that are powerful and readily adapt-
able to large-scale efforts. Engineers have
developed innovative robotic and automation
technologies that are capable of skyrocketing
the number and variety of laboratory experi-
ments. Computer scientists have developed
programming languages and database man-
agement systems that have provided the
basic building blocks for improved environ-
ments for scientific collaboration. And physi-
cists (driven by the need to share the large
amounts of data generated in high-energy par-
ticle physics) have catalyzed the development
of the Internet, which is literally transforming
the ways in which scientific and technical 
collaborations take place.
Never before have biologists been faced
with so much data, and never has the need to
organize the data been greater. Bioinformatics
provides a common language for many disci-
plines, an essential element for applying the
wisdom of biology, chemistry, physics, and
mathematics to a problem. The beauty of the
integration of biology and information science,
claims Botstein, is the ability to make discov-
eries ex post facto from the computer. “We
cannot get to where we need to go using a
frontal assault based on biology alone,” said
Botstein. “We are in the genomic revolution, in
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“Computers allow us to make discoveries on
which we can base beautiful hypotheses that
can then be tested.”
David Botstein
Stanford University
Changing Paradigms in Basic Biology
 High-throughput technologies may be
regarded as an enabling technology for 
modern biology.
 Databases and biological repositories are
essential facilities.
 Sequence databases are revolutionizing the
way we study the structure and function of
biomolecules and cells.
 Sequence data provide powerful insights into
evolutionary relationships and biodiversity.
 Genomic information will be essential 
for understanding biocomplexity in the
environment.
Mary Clutter, National Science Foundation
6which we must figure out a system that makes
sense, use bioinformatics to support the sys-
tem, develop a clear language about the data
and the outcomes, produce a suitable display
system, and apply all this to clinical samples
that were saved in a useful and informative
way.”
On the “digital” side, researchers have
growing access to supercomputers that per-
form millions of operations per second, Internet
backbones that transmit 109 bits of information
per second, and databases that contain 1015
bits of information. Thus, more than ever, new
tools and technologies from engineering, com-
puter science, mathematics, chemistry, and
physics hold great promise for tackling scien-
tific challenges in medicine and biology.
So, How Do We Get There
from Here?
In the postgenomic era of research, multidis-
ciplinary and interdisciplinary research will
command center stage, and some of the most
interesting research will take place at the
boundaries of disciplines and from combining
knowledge from various fields. This requires
team approaches and the collaboration of
multiple individuals from vastly different fields,
such as computational mathematics and
clinical research.
This is not to say that there is no longer
room for the specialist. In many cases, con-
centrated work in a single discipline will
remain the best way to advance the develop-
ment of knowledge. However, basic scientists
working together from more than one discipli-
nary vantage point can advance fundamental
knowledge in important ways that cannot be
attained without such collaboration. This means
that providing opportunities for students to work
collaboratively will be an increasingly impor-
tant part of an education in science.
Good Teaching, Rich 
Classroom and Laboratory
Experiences, Mentoring,
and Hard Work
What is the best way to educate an individual
so that he or she develops the skills needed to
conduct science in the postgenomic era?
There is no simple or single solution, agreed
participants, but there are many good models.
David Botstein talked about the importance of
good teaching and the necessity of today’s
seasoned scientists to return to the classroom.
He believes that many leading scientists are
actively involved in interdisciplinary research
and thus serve as the best examples for
aspiring young scientists. 
Freeman Hrabowski, President, University
of Maryland, Baltimore County, credits one
person in particular for sparking the excite-
ment of countless minority students who have
gone on to careers in science. “Mike Summers,
a Professor of Chemistry and Biochemistry
and Adjunct Professor of Biological Chemistry,
brings joy to his teaching,” said Hrabowski.
“He is a true mentor and is singularly respon-
sible for my campus sending more minority
students on to graduate school in the sciences
than any other institution.”
Hrabowski emphasized the need for
patience and said that many students, espe-
cially those from minority populations, come 
to college unprepared. “This doesn’t mean it’s
over for them,” he commented. “It just means
we need to work with them, even if it means
taking a course twice to get it right.” And, he
added, educational institutions have to get
beyond what he calls the “deficit model” of
teaching. Not all minority students fall into the
category of remediation, and some students
who are superbly talented are not recog-
nized because of the narrowness of our view.
“How do you promote minority students in 
science education?” Hrabowksi challenged.
“You find the best students, insist on a culture
that encourages the best faculty to be
involved, get the students connected to
research, provide environments for group work
across disciplines, and make them repeat their
courses until they are ready to move on.” 
Botstein noted that the entire educational 
system would be more effective if Hrabowski’s
approach were adopted for all students.
In terms of formal training, students must
have adequate breadth in both instruction 
and laboratory experiences, said Nicholas
Cozzarelli, Professor in the Division of Bio-
chemistry and Molecular Biology, University of
California-Berkeley. Cozzarelli routinely asks
his students to be open-minded, to take
chances, and to be prepared for facing 
multiple options. There is nothing wrong with
specialization, added Botstein. Our academic
structures are quite good at producing spe-
cialists, he noted, but these specialists must
have “sockets” so they can communicate with
others with different training and focus.
Nonetheless, these specialists need sufficient
exposure to a broad range of other specialties,
or cross exposure, so that they are able to 
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“How do you promote
minority students in 
science education?”
Hrabowksi challenged.
“You find the best 
students, insist on a 
culture that encourages
the best faculty to be
involved, get the 
students connected 
to research, provide
environments for group
work across disciplines,
and make them repeat
their courses until they
are ready to move on.”
Freeman Hrabowski
University of Maryland, Baltimore County
The David and Lucile Packard Foundation:
Changing the Culture by Example
Historically Black Colleges and Universities 
Science Program
To improve the teaching of science at historically
black colleges and universities (HBCUs), the 
Packard Foundation invites proposals annually from 
a selected set of HBCUs and awards grants totaling
approximately $2 million. The goal of this program 
is to increase the number of young black graduates
qualified in science who can become leaders in their
fields and role models for the next generation of 
students. An advisory panel of eminent black 
educators assists Foundation staff members in 
setting guidelines and evaluating proposals.
Tribal Colleges Science Program 
Often overlooked by the general population, tribal
colleges are now being recognized as an important
part of the educational landscape in America. These
are mostly community colleges founded by American
Indians and located on or near reservations in mid-
western and western states. The goal of the Tribal
Colleges Science Program is to help tribal colleges
better serve the needs of students studying science.
Grants totaling approximately $2 million are awarded
annually. An advisory panel of experts who are
actively involved in tribal colleges assists Foundation
staff members in evaluating proposals and monitoring
grants in this area.
8realize when they have reached their limita-
tions and should seek help. To illustrate the
need for cross exposure, Thomas Cech, 
President, Howard Hughes Medical Institute,
quoted biologist Lewis Thomas, who wrote
If you want a bee to make honey, you do
not issue protocols on solar navigation or
carbohydrate chemistry, you put him
together with other bees....And you do
what you can to arrange the general
environment around the hive. If the air is
right, the science will come in its own
season, like pure honey.
Stephen Burley, Rockefeller University,
described the Burroughs Wellcome Fund
Interfaces Training Program, which aims to
create an environment in which “cross- 
pollination” can occur. The Program has a
unique structure. It has no formal departments
and 75 faculty in chemistry, physics, and 
biology who report to the president. Two 
centers—one in physics and biology and one
in chemistry and biology—comprise collec-
tions of faculty with common interests, who
conduct collaborative research and training.
The long-term goal of this approach is to bring
quantitative tools to bear on problems in 
biology. Burley admits that this strategy is
likely to increase the training time of new 
scientists.
Cech suggested that to understand train-
ing and career models that work, we should
look to the common denominators in the 
training of individuals who have successful
careers as interdisciplinary scientists working
with teams of diverse individuals. He cited
Howard Hughes Medical Institute Investi-
gators Sharon Long, Stanford University,
Stephen L. Mayo, California Institute of 
Technology, and Roderick MacKinnon, 
Rockefeller University, as exemplars of 
individuals trained in multiple disciplines 
who conduct interdisciplinary research. 
Overcoming Barriers to
Interdisciplinary Research
and Training in the Basic
Sciences
Many panelists cited the traditional and per-
sistent barriers to interdisciplinary research
and training that must be addressed if post-
genomic biomedical research is to reach its
full potential. These include attitudinal resis-
tance; differing research methodologies and
communication barriers among disciplines;
the length and depth of training in a single field
that is needed to develop scientists who will
be successful in competing for funds; the 
difficulty in forging a successful career path
outside of the single-discipline structure;
impediments to obtaining research funding for
interdisciplinary research early in one’s career;
the scarcity of interdisciplinary departments in
academe; and the perceived lack of outlets for
the publication and dissemination of interdis-
ciplinary research results. 
Cozzarelli noted that it takes certain inter-
personal skills to conduct interdisciplinary
research and that laboratory training alone
might not be sufficient to develop those skills.
Moreover, interdisciplinary research teams
must be led by individuals who understand the
challenges of group dynamics and who can
provide appropriate leadership. 
Academic departments create the environ-
ment within which education and research
occur and often perpetuate disciplinary 
identity through training and mentoring 
practices, said Howard Hughes Medical Insti-
tute’s Cech. This can inhibit interdisciplinary
research, because investigators intrigued by
the same multifaceted problem are likely to
work in different departments. Moreover, pro-
motion and tenure policies and practices,
which serve as tremendous motivators and
controlling devices for academic scientists,
also are driven by departmental cultures. In
addition, the priority given to contributions in
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Sharon R. Long, Ph.D. 
Dr. Long, a Howard Hughes Medical Institute
Investigator, is also Professor of Biological 
Sciences at Stanford University and Adjunct Pro-
fessor of Biochemistry at Stanford University
School of Medicine. She received her B.S. degree
from the California Institute of Technology, in the
Independent Studies Program, and her Ph.D.
degree in cell and developmental biology from
Yale University. Dr. Long has been awarded a
MacArthur Prize fellowship and is a member 
of the National Academy of Sciences. She is a 
fellow of the American Academy of Arts and 
Sciences and the American Academy of Micro-
biology. Her laboratory combines a number of
approaches—including genetics, biochemistry,
and cell biology—in the study of a symbiotic 
bacterium-plant association to ask how new cell
division, growth, and gene expression arise in
each partner due to stimulation from the other.
Dr. Long’s team has identified and cloned the
genes in the bacterium that cause it to stimulate
nodule formation in its host and has found that
these genes are only expressed in the bacterium
when in the presence of a signal from the plant
host root. This signal is a small molecule in 
the chemical category known as flavonoids.
Flavonoids and related compounds have been
proposed to have health benefits as components
of human diets, but no specific mechanisms have
been established.
Stephen L. Mayo, Ph.D.
Dr. Mayo is Assistant Professor of Biology at 
the California Institute of Technology and
Adjunct Assistant Professor of Biochemistry and
Molecular Biology at the University of Southern 
California School of Medicine, Los Angeles. He is
a Howard Hughes Medical Institute Assistant
Investigator. Dr. Mayo received a B.S. degree in
chemistry from Pennsylvania State University and
a Ph.D. degree in chemistry from the California
Institute of Technology, where he studied bio-
logical electron transfer. Dr. Mayo developed a
rule-based molecular mechanics force field as 
a Miller Fellow at the University of California,
Berkeley, and studied hydrogen/deuterium exchange
reactions in proteins as a postdoctoral fellow with
Robert Baldwin at Stanford University School of
Medicine. Dr. Mayo is also a Rita Allen Foundation
Scholar, a Searle Scholar, and a Packard Fellow.
His laboratory focuses on the coupling of theoret-
ical, computational, and experimental approaches
for the study of structural biology. In particular, he
has developed quantitative methods for protein
design, with the goal of developing a systematic
design strategy that is called protein design
automation.
Roderick MacKinnon, M.D.
Dr. MacKinnon, a Howard Hughes Medical Institute
Investigator, is also Professor of Molecular 
Neurobiology and Biophysics at Rockefeller 
University. He received a B.A. degree in 
biochemistry from Brandeis University and an
M.D. degree from Tufts University School of 
Medicine. He completed a medical residency at
Beth Israel Hospital, Harvard Medical School, and
postdoctoral work at Brandeis. Dr. MacKinnon
has received the Young Investigator Award from
the Biophysical Society and the prestigious 1999
Albert Lasker Medical Research Award. His work
focuses on ion channels, membrane-spanning
proteins that form a pathway for the flow of inor-
ganic ions across cell membranes. Ion channels
are extraordinarily simple physical systems, and
yet they are responsible for all electrical signaling
in biology. Among their many functions, ion
channels control the pace of the heart, regulate
the secretion of hormones into the bloodstream,
and generate the electrical impulses underlying
information transfer in the nervous system. 
Dr. MacKinnon’s laboratory relied on molecular
biological and electrophysiological techniques,
but when the lack of molecular structure limited
their progress, they embraced the distant field of
x-ray crystallography. The result was a much-
heralded atomic-level photo of the potassium ion
channel.
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The Face of Modern Biomedical Research: 
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areas recognized by departmental struc-
tures may fail to nurture interdisciplinary
approaches.
Departmental chairs are generally recruited
or appointed because they are outstanding
examples of the discipline that is represented
by the department. It may be difficult, there-
fore, for junior faculty whose interests range
beyond the formal subject matter of a given
department to be viewed as either making
substantial contributions to the field or as 
meriting advancement in a given department.
The issues surrounding disciplinary identity
can spill over into training. Current depart-
mental structures, particularly the lack of
mechanisms for mentoring in specific training
programs, may restrain the development 
of interdisciplinary researchers. With the
increased competition for research funds,
many departments have developed models
for mentoring junior faculty, both in the grant-
writing process and in obtaining hands-on
research experience early in projects. But all
too often, junior investigators in a department
are limited to mentoring or training opportuni-
ties provided by the faculty of that department.
Finally, a scientist’s research reputation is
essential to obtaining research support, gain-
ing employment, getting promotions, and win-
ning grants. Authorship on papers is perhaps
the single most important predictor of one’s
success in these areas. In the past, the size 
of collaborative groups has posed problems 
for interdisciplinary researchers, particularly
when it came to listing authors on publications.
Fortunately, this trend is reversing. However,
the important contributions of those who 
historically have been considered the “hand-
maidens” or technical support in large in-
terdisciplinary efforts (computer scientists,
statisticians) are still often under-recognized.
Until more academic departments are will-
ing to acknowledge individual contributions 
to an interdisciplinary research effort, rather
than author position on a journal article, young
investigators will be dissuaded from engaging
in interdisciplinary research with multiple 
collaborators. That “luxury” will be reserved 
for the tenured professor who has already
established a research career.
Private Funders Making 
a Difference
With the strong economy of the past decade,
new philanthropic efforts have emerged. Total
annual giving by over 44,000 foundations 
is estimated to be more than $20 billion. The
scientific share of philanthropy, however, is not
increasing, reported Jaleh Daie, Director of
Science Programs at the David and Lucile
Packard Foundation, who noted that only
about 300 foundations regularly support 
science.
Even though the private contribution cannot
match that of the federal government, said
Daie, philanthropy plays a special role. Foun-
dations can leverage off of public programs 
to realize a substantial impact. Private givers
can catalyze innovation by jump-starting
emerging fields, she added. In addition, they
can support alliances that typically would not
be supported through public mechanisms.
Perhaps one of the most rewarding roles of
philanthropy, said Daie, is to “prime the pump”
by supporting young investigators at the
beginning of their careers.
Investing in the Future
Philanthropic organizations have long made
critical contributions to support the early
careers of basic scientists. The importance
of private support of young investigators
was emphasized by Donella Wilson,
National Scientific Program Director for the
American Cancer Society, which spends
$100 million annually on research award
programs that are peer reviewed by external
committees. In recent years, an oversight
group has recommended that the Society
refocus its research awards on beginning
investigators to help them become securely
established.
Similarly, the American Heart Association
has carved an important niche in supporting
the development of beginning investigators
and offering innovative funding mechanisms
to stimulate research in promising science
areas, reported Susan Barnett, Vice Presi-
dent of Research Administration. Although
the federal government provides more money
for research through the National Heart,
Lung, and Blood Institute, National Institutes
of Health (NIH), the Association makes a sub-
stantial contribution in a more focused way. In
1999, it spent $130 million on research,
received more than 3,000 applications, and
funded 1,000 awards. Of this, $64 million was
dedicated to beginning investigators (not
more than four years from first faculty
appointment).
The Association also supports the career
development of highly promising clinician-
scientists and Ph.D.s who have recently
acquired independent status. This is done by
encouraging and adequately funding high-
quality, innovative research projects for which
financial support has not been previously
obtained from any other agency. 
The same is true for the W.M. Keck Foun-
dation, through its Distinguished Young
Scholars in Medical Research Program. This
Program is designed to promote the early
career development of a select group of the
country’s brightest young biomedical scien-
tists. It supports groundbreaking research
addressing the fundamental mechanisms of
human disease by young investigators who
exhibit extraordinary promise for independent
basic biological and medical research and
who demonstrate a capacity for future acade-
mic leadership.
According to Maria Pellegrini, Keck Program
Director for Science Engineering and the Lib-
eral Arts, the Foundation invites 30 outstand-
ing research universities and independent
research institutes annually each to nominate
one faculty member who is in the second to
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The Keck Graduate Institute of 
Applied Life Sciences: Supporting
“Good Human Protoplasm” 
Launched in 1997 with a $50 million founding 
grant from the W.M. Keck Foundation, the Keck
Graduate Institute of Applied Life Sciences is the
first graduate school in the country solely dedicated
to the marriage of the life sciences and the subdis-
ciplines of engineering. Reflecting the significance—
and potential—of this endeavor, this is the second
largest grant ever made by the Foundation for a 
single project.
The Keck Graduate Institute of Applied Life 
Sciences seeks to build on the profound insights
into the understanding of biological processes now
emanating from corporate and government research
laboratories and to play a central role in translating
the vast potential of these discoveries into practical
applications by preparing a uniquely qualified class
of professionals for responsible and productive
careers in life science-based organizations. In the
words of Maria Pellegrini, Program Director, the 
goal is to support “good human protoplasm.”
Specifically, the Graduate Institute will focus 
initially on three or four “niches” where it can 
build distinctive competencies. These areas of 
concentration, which will be chosen from among
such fields as biochemical process engineering, 
bio-instrumentation, biomaterials, medical devices,
bioinformatics, and biomechanics, will be comple-
mentary to one another and will have strong cross-
linkages with regard to research opportunities,
industrial interests, and curricular requirements. 
A particular feature of the Graduate Institute 
will be its emphasis on giving students a full 
understanding of the climate and culture in which
scientists and technologists in industry must func-
tion. Accordingly, instruction in management,
ethics, economics, systems, and policy issues, as
well as substantial team-based project work, will 
be central to the curriculum.
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fourth year of his or her first tenure track posi-
tion. Up to five recipient institutions receive 
a maximum of $1 million each. These grants
support the research activities of the selected
candidates for a period of up to five years and
enable the institution to purchase necessary
equipment and resources to facilitate the
investigative process.
The Keck Foundation’s goal is to provide
these institutions and their young scientists
with the opportunity to investigate promising
and unproven new ideas for which funding
can be difficult to obtain, even for established
researchers with steady funding streams.
Pellegrini emphasized that these awards are
not intended to remove these scientists from
the academic environment or to relieve them
of their teaching responsibilities and the 
grant-writing and administrative burdens of
running a laboratory, all of which the Founda-
tion believes are important parts of every
young scientist’s training.
Targeting Research
In addition to supporting new investigators
while they establish their research careers,
philanthropy can target areas of research that
are not supported or that are underfunded.
This is particularly true for voluntary health
agencies, which have targeted missions and
tangible goals. 
For example, the Juvenile Diabetes Foun-
dation makes a crucial contribution by focus-
ing on research that has the promise of
producing a cure for Type I diabetes. A sec-
ondary outcome of research support is the
training of new investigators in research that 
is important to the Foundation’s mission. To
illustrate, since September 1998, the Founda-
tion has funded nine new research centers—
large-scale, multidisciplinary, high-priority
initiatives that are focusing on solving spe-
cific problems within the three priority goal
areas: 1) restoration of normal blood sugar
levels; 2) avoidance of and improved treat-
ment for complications; and 3) prevention of
diabetes and its recurrence. Through the initi-
ation of human clinical trials, the centers will
use the expanded diabetes knowledge base
to move research out of the laboratory and into
the lives of those with diabetes. 
Robert Goldstein, the Foundation’s Chief
Scientific Officer, emphasized that the goal of
the Foundation, and of organizations like it, is
to commission scientists to solve a problem,
such as islet cell transplantation. “We recog-
nize that training is a component of that goal, 
if not the primary goal," he added.
The American Heart Association’s Barnett
also commented on the targeted approach to
research funding. For example, this year the
Association set specific content goals for its
research program, including patient care and
outcomes research, brain blood vessel biol-
ogy, functional genomics, and stem cell
organogenesis.
Many voluntary health agencies rely on lay
reviewers of research to help them meet their
goals. The Juvenile Diabetes Foundation’s
Goldstein noted that the lay review conducted
after scientific review adds a valuable compo-
nent to research evaluation. He added that the
Foundation adopts a proactive approach to
the scientific research community by introduc-
ing early in the process the priority problems it
wants to address using a flexible, fast-track
“There are times when the interests and 
goals of voluntary health groups and federal
funders overlap and collaboration is 
in order.” Robert Goldstein
Juvenile Diabetes Foundation
review of applications for research projects.
Not all voluntary health agencies have the
resources to conduct rigorous peer review 
of protocols. The Life Sciences Research
Foundation supports an annual postdoctoral
fellowship program, which provides built-in
peer review for funders, at no additional cost.
Juried by a panel of Nobel laureates and other
distinguished scientists, these fellowships are
highly competitive and have been offered
since 1983. Dr. Donald Brown, Life Sciences
Research Foundation President, said the
Foundation provides a cost-effective way for
funders to support research training. 
Collaborating with Public Funders
Although it is rare, some private funders have
entered into productive collaborations with
federal funders. For example, from 1986 to
1998, the Alfred P. Sloan Foundation provided
support for research in molecular evolution.
Beginning in 1994, the Foundation operated a
jointly sponsored program with the National
Science Foundation in this area, consisting of
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Progress in Electronic Grantsmaking
Dr. Joseph Perpich, Vice President for Grants and Special Programs, Howard Hughes Medical
Institute, invited participants to share their ideas and views regarding the “new world of 
electronic grantsmaking” and introduced a panel of representatives of several funders of bio-
medical research training that have undertaken the development of Web-based systems for
electronic grantsmaking. (See also Appendix A.)
Ellis Rubinstein of the American Association for the Advancement of Science discussed
new enhancements that have been made to the Association’s successful online database and
career development sites, GrantsNet and NextWave, and T. J. Koerner, Director of Research
Information Management at the American Cancer Society, Carolyn Miller, Director of 
the FastLane Project, the National Science Foundation, and George Stone, Chief of the 
Commons, Extramural Inventions and Technology Resources Branch, NIH, demonstrated
their online grant application systems and talked about current and future challenges and
opportunities in the area of electronic grantsmaking. Participants agreed that the four 
systems created by these funders clearly demonstrate the value of Web-based systems for
handling applications and grants online and the benefits of sharing data.
Dr. Perpich provided an overview of the Howard Hughes Medical Institute online physician-
postdoctoral competition program and called participants’ attention to the Institute’s exciting
new virtual discussion forum (www.hhmi.org/grants/forums.htm). With a section devoted
to topics in electronic grantsmaking, as well as one on general grantsmaking issues, the 
virtual forum will provide both public and private funders of biomedical research training
with an opportunity to explore a variety of issues, including the use of current and develop-
ing technologies in data sharing among multiple systems that have not been built around
common data fields. 
In opening remarks, Enriqueta Bond, President of the Burroughs Wellcome Fund, also
focused on the importance of sharing information, commenting that it is clear that private
funders can be more strategic about their investments if they know what others are doing
and have an understanding of current trends, challenges, and opportunities, including 
those for partnerships. John Stevens, interim Strategic Business Manager for the American
Cancer Society’s Research and Health Professional Training Program and Vice President for
Extramural Grants, added that the meeting is a critical component in spreading the word
about what grants are available and ways in which individuals can apply for those awards.
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two parts: a Postdoctoral Research Fellow-
ship, which provided 18 awards per year for
two-year postdoctoral fellowships, and a
Young Investigators Program, which provided
awards of $100,000 to five applicants in the
first few years of their independent research
careers.
The Alfred P. Sloan Foundation also has 
collaborated with the U.S. Department of
Energy (DOE), reported Program Director
Michael Teitelbaum. In 1995, the Foundation
approved a Postdoctoral Fellowship Program
in Computational Molecular Biology, jointly
sponsored with the Office of Health and 
Environmental Research of DOE, to support
up to 10 postdoctoral fellowships each year.
The Program is aimed at catalyzing career 
transitions into computational molecular biology
from physics, mathematics, computer science,
chemistry, and related fields. Teitelbaum said
the programs have worked well, as long as 
the funds contributed by each donor are kept
separate.
Programs of Federal Funders
Several federal funders provide critical training
support for basic biological and biomedical
scientists. Federal support tends to be broad
based rather than categorical, although some
training grants can target specific areas of
research in which trainees can be supported.
For example, the National Institute of General
Medical Science (NIGMS), NIH, provides
predoctoral training grants in bioinformatics
and computational biology; biotechnology;
cellular, biochemical, and molecular sciences;
chemistry-biology interface; genetics; mole-
cular biophysics; pharmacological sciences;
and systems and integrative biology, reported
Marvin Cassman, NIGMS Director. 
The primary mechanism through which 
NIH supports predoctoral and postdoctoral
trainees and fellows is the National Research
Service Award. NIGMS and other NIH Institutes
also make awards to institutions for the train-
ing of predoctoral students and postdoctoral
researchers. In addition, the NIH Medical 
Scientist Training Program (MSTP), leading to
the combined M.D.-Ph.D. degree, supports
the integrated medical and graduate research
training that is required for the investigation
of human diseases.
NIGMS’s goal in its predoctoral programs is
to provide trainees with broad access to
research opportunities across disciplinary and
departmental lines while maintaining high
standards of depth and creativity. Cooperative
involvement of faculty members from several
departments or doctoral degree programs is
one essential aspect of this multidisciplinary
emphasis. Another is breadth in research
training instruction, with regard to both the cur-
riculum and laboratory rotations. Students are
typically supported by the NIGMS predoctoral
training grant for one to three years of gradu-
ate studies in Ph.D. programs or for two to six
years in the M.D.-Ph.D. programs, and by
other mechanisms in subsequent years. The
rationale for this approach is that students
supported by the training grant have greater
flexibility early in their studies in making crucial
choices about courses and research fields.
However, the current stipend level for FY 2000
for predoctoral trainees of $15,060 per year is
far too low, said Cassman.
The public sector historically has been an
important source of funds for training minority
scientists. For example, NIGMS participates in
The primary mechanism through which NIH 
supports predoctoral and postdoctoral trainees and
fellows is the National Research Service Award.
an NIH-wide program of individual predoctoral
fellowship awards for minority students. These
awards provide up to five years of support 
for research training leading to a Ph.D. or
equivalent research degree, a combined
M.D.-Ph.D. degree, or another combined pro-
fessional doctorate-research Ph.D. degree in
the biomedical or behavioral sciences. Eligible
for this award are highly qualified students
who are members of minority groups that 
are under-represented in the biomedical or 
behavioral sciences in the United States. The
intent of this fellowship program is to encour-
age these students to seek graduate degrees,
thus furthering the goal of increasing the 
number of minority scientists who are pre-
pared to pursue careers in biomedical and
behavioral research.
John Ruffin, Associate Director for Research
on Minority Health, Office of the Director, NIH,
noted that many programs aimed at minority
students are efforts to retain students who are
already interested in the sciences and that it is
an important federal role to capture the interest
of students who currently are not thinking
about science. In response to these concerns,
NIH offers its investigators supplements to
attract under-represented minorities into bio-
medical and behavioral research throughout
the continuum from high school to the faculty
level. In addition, the Initiative for Minority 
Students: Bridges to the Baccalaureate
Degree provides training that leads to the 
baccalaureate degree for selected students
from under-represented minority groups. The
objective is to encourage the development of
new and innovative programs and the expan-
sion of existing programs to improve the aca-
demic competitiveness of under-represented
minority students and to facilitate the transition
from two-year junior or community colleges to
four-year institutions.
Other NIH Institutes support training pro-
grams of importance to their research portfolio.
The National Human Genome Research 
Institute (NHGRI) has a small but targeted 
program to support predoctoral and post-
doctoral training in areas of importance to 
the NHGRI mission, such as the interfaces
between biology and physics, reported Elke
Jordan, NHGRI Deputy Director. NHGRI 
also supports numerous career development
awards, such as the Genome Scholar Devel-
opment and Faculty Transition Award, made to
promising new genome researchers to estab-
lish an independent research program in
genomic research and analysis and to secure
a tenure-track appointment in an academic
institution in the United States.
Jordan also described NHGRI’s Curriculum
Development Award in Genomic Research
and Analysis, which supports the develop-
ment of courses and curricula designed to
train interdisciplinary scientists who combine
knowledge of genomics and genetics
research with expertise in computer sciences,
mathematics, chemistry, physics, engineering,
or closely related sciences. Jordan anticipates
that these courses or curricula will be useful to
students and scientists who wish to develop
new conceptual approaches to genome
research and analysis or to organize, analyze,
or interpret large data sets resulting from
genomic and genetics research. 
The National Science Foundation is another
important supporter of training in the basic
biological sciences, but it also provides
essential backing for education in mathe-
matics, physics, and chemistry. Moreover, 
the Foundation historically has emphasized
the integration of research and education,
because, according to Assistant Director Mary
Clutter, “the best place to educate people is in
the discovery-rich environment of research.”
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“The best place to educate
people is in the discovery-rich
environment of research.”
Mary Clutter
National Science Foundation
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National Science Foundation programs
include Research Experiences for Undergrad-
uates, Collaborative Research at Under-
graduate Institutions, Graduate Teaching 
Fellows in K-12 Education, Faculty Early
Career Development, and Postdoctoral 
Fellowships. An important new program, the
Integrative Graduate Education and Research
Traineeship (IGERT) Program, was initiated in
1997 to meet the challenges of educating
Ph.D. scientists and engineers with the multi-
disciplinary backgrounds and the technical,
professional, and personal skills needed for
the career demands of the future.
The IGERT Program is intended to catalyze
a cultural change in graduate education 
for students, faculty, and universities by
establishing new and innovative models for
graduate education in a fertile environment
for collaborative research that transcends 
traditional disciplinary boundaries. It is also
intended to facilitate greater diversity in stu-
dent participation and preparation and to
contribute to the development of a diverse,
globally aware science and engineering
workforce.
Goals for Private Funders
Biology in the postgenomic era will require
new sets of skills and individuals who can
establish themselves successfully in rapidly
moving fields of research. Clearly, philan-
thropy has played and will continue to play an
important part in jump-starting the careers of
new investigators, particularly during the 
transition from postdoctoral fellow to faculty
member. The receipt of funding from an organ-
ization such as the American Cancer Society
or the American Heart Association, for exam-
ple, can be the push that launches a research
career. In addition, philanthropy, because its
mission is often problem based, can support
inherently interdisciplinary research and train-
ing that breaks new ground.
Several meeting participants emphasized
the value of private funds in trying to change
the culture and structures of research and
education. Because some of the most exciting
work of the postgenomic era will occur at the
interface of disciplines, private funders can
provide the “glue” needed to force faculty to
work together toward research and educa-
tional goals. Private foundations can provide
financial incentives to institutions to change
behavior and to encourage scientists to teach.
Two currently funded American Cancer
Society trainees, Anne Blackwood, M.D., and
Michelle Tallquist, Ph.D., emphasized the
need for transitional training mechanisms to
teach scientists how to move from being a 
student to becoming a successful faculty
member; manage a laboratory; ensure contin-
ued education; and receive departmental
credit good toward professional promotion
while engaging in interdisciplinary research
projects. Also mentioned was a need for more
grant funding for junior faculty past the five-
year faculty career mark, which should also
provide possible internship experiences for
alternative career choices.
Unlike the public sector, because of its 
mission and more limited resources, private
funders can be elitist, choosing the best stu-
dents and developing them faster. Finally, the
private sector frequently has the freedom to
take chances and change directions quickly.
The following conclusions and recommen-
dations emerged from the sessions on training
basic biomedical scientists:
1. In the postgenomic era of research, 
multidisciplinary and interdisciplinary
research will command center stage.
Some of the most interesting research
will take place at the boundaries of dis-
ciplines and from combining knowledge
from different disciplines, requiring team
approaches and the collaboration of
many individuals from vastly different
fields, ranging from computational math-
ematics to clinical science.
2. The need for team approaches to scien-
tific research raises questions about how
to invest private dollars to support such
work beyond the center or program
grant approaches. Several examples of
possible approaches to meeting this
goal were cited, including providing
grants to support clusters of faculty in
order to build expertise and collabora-
tions and establishing programs that
force collaborative research.
3. The development of human capital with
a set of new skills is essential. Support 
of postdoctoral students and new fac-
ulty is important, but more is needed.
Philanthropy must also invest in the
development of scientists from under-
represented groups, provide appropri-
ate support for foreign students, and
recognize that with the globalization of
the research enterprise, it will be vital to
provide experiences for U.S. students
abroad.
4. The changing paradigm of research
calls for innovations and changes in edu-
cation of scientists along the spectrum 
of K-12, undergraduate education, and
graduate education. Some examples
identified ranged from such simple inno-
vations as requiring biology courses for
all engineering students, to the develop-
ment of a valued terminal master’s
degree in bioinformatics, to wholesale
changes in undergraduate education.
The increasing need to value teaching 
in all settings could be improved by 
making grants that free the time of
scholar/researchers for teaching.
5. The private sector can facilitate some
areas or types of research more easily
than can public agencies, such as
research with embryonic stem cells or
prehypothesis-driven work to assemble
and organize information that can pro-
vide a platform for hypothesis-driven
work and infrastructure support.
6. The unfolding of the postgenomic era
raises many ethical issues that deserve
consideration and study as well as the
establishment of guidelines if private
sector support is considered for areas in
which controversy exists. 
7. Partnerships among private funders and
between the public and private sector
will be valuable in moving the post-
genomic research and training agenda
forward and in leveraging the invest-
ments of both private sector and public
sector groups.
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Supporting Beginning Cancer Research
Investigators
The American Cancer Society, a community-based
volunteer health organization, is the largest source of
private, not-for-profit cancer research funds in the
United States. A major focus of its research program
is the support of cancer investigators early in their
careers.
Research Scholar Grants for Beginning Investigators
are awarded to support basic, preclinical, clinical, 
or epidemiologic research projects initiated by inves-
tigators in the first eight years of their independent
research careers. Initial awards are made for up to
four years and up to $250,000 per year, including 
25 percent indirect costs. 
Postdoctoral Fellowships support the training of
researchers who have just received their doctorate.
Awards are made for one to three years, with progres-
sive stipends of $28,000, $30,000, and $32,000 per
year, plus a $2,000 per year institutional allowance. 
Clinical Research Training Grants for Junior Faculty
support the training of junior faculty within the first
four years of independent faculty appointment to
conduct mentored clinical, epidemiological, or health
policy and outcomes research. Awards are made 
for up to three years for up to $150,000 per year,
including 25 percent indirect costs.
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The Future of
Clinical Research
Training
In his keynote speech, Richard Lifton, Howard Hughes Medical Institute Inves-tigator and Director of the Program in Cardiovascular Genetics at the Boyer
Center for Molecular Medicine at Yale University, commented that we have moved
beyond relying on the “handshake test” to define clinical research. “No longer
does clinical research require that an investigator and patient be in the same
room,” he added. With the advent of molecular biology, extensive research now
can be done on the pathogenesis and pathophysiology of human disease by
working at the DNA level on stored samples.
This advance gives researchers the ability to identify the underlying causes of
disease based entirely on the genetic nature of the disorder, without prior knowl-
edge of its pathophysiology. Thus, the paradigm that has emerged of positional
cloning of disease genes has revolutionized our understanding of human disease,
affecting every medical discipline, stressed Lifton. He added that as of February 15
of this year, 990 diseases with an inherited component had been characterized 
at the molecular level, most within the past five years.
Although the majority of these are single-gene disorders, the genetic under-
standing of these disorders is central to discerning the fundamental physiologic
pathways that may be relevant to more common forms of disease. In addition, gene
targets in rare diseases may provide opportunities for therapeutic intervention for
common disorders. Lifton cited the example of the groundbreaking research on
familial hypercholesterolemia, conducted by Michael Brown and Joe Goldstein.
Although hypercholesterolemia is a rare disease, the work of Brown and Goldstein
led to the eventual development of HMG CoA reductase inhibitors, which have
had a profound effect on reducing risk of coronary artery disease in the general
population.
The challenge for clinical research is that
most common diseases are complex, multi-
etiologic disorders in which a multiplicity of
genes interact with each other and with envi-
ronmental factors, revealing subtle variations
in DNA. Common genetic variations are
attracting enormous interest because it is 
suspected that they may contain clues to
inborn susceptibility to common diseases.
Clinical research must find the resources and
intellectual capital to locate large enough
cohorts of patients with good enough pheno-
types to relate common variants in the popu-
lation. The goal is to determine how many
genes are imparting an effect in any given 
disease and to evaluate the magnitude of 
the effect.
To illustrate, Lifton described recent
research on Alzheimer’s disease, which was
once thought to be multifactorial and complex,
but which is now emerging as a nearly mono-
genetic disease. The inheritance at a single
locus of a particular allele of an apolipoprotein
contributes about 50 percent of the risk of
development of Alzheimer’s disease. Thus, a
single gene has a relatively large effect.
In addition to genomics, other companion
technologies will advance the goals of clinical
research, such as the use of chips to monitor
expression of genes. This tool has the poten-
tial to identify pathways that are altered in 
disease physiology, and they can be used 
as diagnostic tests (molecular diagnostics).
Eventually, this technology will allow clinical
scientists to tailor treatment to underlying
abnormalities. In addition, functional MRI and
NMR spectroscopy provide new tools to 
investigate fundamental physiology in living
patients, such as the study of glucose trans-
port in patients with diabetes. The study of in
vivo biochemistry in humans can only be 
conducted with the participation of clinical 
scientists, particularly the physician-scientist,
emphasized Lifton.
“With the advent of the Human Genome
Project we are going from an open-ended
problem to a closed biological problem,” said
Lifton. “This will have profound effects on the
understanding of clinical medicine. In a short
period of time we will know all of the common
genetic variants. It will take the clinical scien-
tist to figure out how to tie all the variants to
particular diseases.” 
Lifton argued that after the genome is
mapped, science will have to rely on clinical
investigation to conduct gene-based studies,
to redefine the biology and the phenotypes of
disease, and to refine diagnostic classifica-
tions. He added that clinical research is by
definition interdisciplinary and that clinical
investigators are comfortable with that para-
digm and noted that unlike the basic scientist,
the clinical scientist routinely seeks consulta-
tion from other specialists to understand a 
clinical problem.
Yet, the funding trend has been away from
the physician-scientist, a phenomenon that
has been repeatedly noted with dismay over
the past decade. Lifton’s view is optimistic,
however, because he believes clinical
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The challenge for 
clinical research is 
that most common 
diseases are complex,
multi-etiologic disorders
in which a multiplicity 
of genes interact with
each other and with 
environmental factors,
revealing subtle 
variations in DNA.
Richard Lifton
Yale University
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advances cannot come from the human
genome without the participation of the trained
clinician. The opportunities will draw the intel-
lect, as long as the environment is conducive
to the physician trained in basic biology. He
referred to a number of model programs, such
as the NIH MSTP, that have been essential
mechanisms for training physician-scientists.
Still, Lifton said, economic forces, such as
medical school indebtedness and pressures
from academic health centers to increase
patient revenues, continue to dissuade physi-
cians from a research career. 
Who Should Conduct 
Clinical Research?
Edward Holmes, Dean of the School of Medi-
cine at Duke University, posed a schema for
categorizing those who conduct clinical
research. He believes that the training and
research pathways of each type of investigator
are unique and that the various categories
reflect the need for diverse mechanisms of
support. 
 Professional clinical investigator – spends
80 percent of his or her time conducting
clinical research (conducts Phase III
clinical trials, outcomes research, epi-
demiology); often has advanced training
obtained beyond the M.D. (for example,
M.S., M.P.H.).
 Clinician investigator – primary effort is in
patient care, but may work with a profes-
sional clinical investigator; has no spe-
cial training in research; is the hands-on
team member in terms of patient contact
and therefore is a critical player.
 Physician-scientist – spends 80 percent
of his or her time conducting research,
typically laboratory investigation explor-
ing the pathogenesis of human disease;
works at the interface between the 
laboratory and the clinic (may conduct
Ethical Issues Facing Biomedical
Research
R. Alta Charo, Professor of Law and Medical
Ethics at the University of Wisconsin, provided a
broad view of emerging ethical issues in biomed-
ical research. In addition to highlighting substan-
tive topics that are the focus of debate—such as
stem cell research, reproductive technology, gene
patenting, and international research—Charo
noted the special concerns that arise when
research is conducted with human subjects.
In the area of protecting human subjects in
research, clinical science must contend with
 The great divide between research that is 
regulated and research that is not, because of
source of funding.
 The challenge of distinguishing between 
experimental therapy and research.
 The determination of what defines a human
subject in research and the assurance of 
privacy protection.
 The technological imperative and the drive to
produce versus the assurance of patient safety.
 The changing paradigm of research participation,
with patients now demanding access to clinical
trials.
The private sector can play an important role in
 Extending protections to all human subjects 
in research, regardless of funding source.
 Developing and enforcing a code of ethics for
supported investigators.
 Ensuring the protection of vulnerable populations.
 Not supporting research that masquerades as
care.
 Supporting responsible multicultural initiatives
in research.
Phase I and II clinical trials); has
advanced research training.
 Ph.D. translational scientist – conducts
clinically oriented research, such as 
outcomes research, health services
research, biostatistics, epidemiology,
animal models of human disease, and
molecular analysis; nearly always works
as a member of a team.
It is the physician-scientist group that is
most threatened in major medical centers,
said Holmes, because of the time, effort, and
expense of training. The most effective point 
of entry for these individuals is the medical 
student level, and students must be enticed
early so they can make their career choice at
an appropriate time. Holmes would like to be
able to offer 40 percent of his students the
opportunity to take advanced training in sci-
ence during the time they are receiving their
medical education.
Holmes believes that the issue is not so
much whether Ph.D.s go to medical school or
whether medical students should get Ph.D.s,
but rather that both groups must work together
to be successful. “A medical school cannot 
be successful if it only has a single category 
of researcher,” he added, and “awards that
encourage people from basic and clinical 
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Burroughs Wellcome Fund: 
Targeting Clinical and Interdisciplinary Research
The Burroughs Wellcome Fund supports several programs designed to
foster clinical and interdisciplinary research. Clinical Scientist Awards
in Translational Research are intended to foster the development, pro-
ductivity, and mentoring capabilities of established physician-scientists
who will strengthen translational research—the two-way transfer of
information from the laboratory bench to clinical medicine.  
Career Awards in the Biomedical Sciences are available to both
Ph.D.s and M.D.s and provide support during the critical transition
from training to gaining research independence. Approximately 24
awards are made annually. Each award provides research and salary
support for two to three years of postdoctoral training and three years
at the faculty level. The awards are transportable, and preliminary 
evaluation data indicate awardees have been highly successful in 
securing faculty positions.
Through its Interfaces in Science Program, the Fund supports the
interdisciplinary training of promising graduate and postdoctoral stu-
dents from the physical, chemical, and computational sciences so they
can better apply their unique knowledge and talents to biological prob-
lems. Awards are made to institutions that promote interdisciplinary
training. Degree-granting institutions in the United States and Canada
are invited to propose graduate or postdoctoral training programs, or a
combination of both.
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science to work together are the most efficient
means to meet that goal.” Holmes believes this
approach should be especially attractive to
private philanthropy, because of its interest in
translational research, which cannot be done
by a single individual or through a single
approach.
Models of Training:
Building Bridges Between the
Basic and Clinical Sciences
Irwin Arias, Chairman and Professor in the
Department of Physiology and Professor of
Medicine at the Tufts University School of
Medicine, provided another view of filling the
gap between basic and clinical research. “Any
gap you want to cross necessitates a bridge,”
he said. “There are many components to a
bridge, and we should look at all of them to
see how they come together to facilitate the
overall structure.” Quoting German pathologist
Werner Kollath, Arias said, “Much is known,
but unfortunately in different heads.”
Arias described the Pathobiology Program
at Tufts University, of which he is the director.
For the past 13 years, the Program has been
conducted for Ph.D. students, fellows, and
faculty, based on the following principles: 
 Because they are interested in a career
that bridges basic science with human
health, virtually all graduate students
select a basic science department in a
medical school rather than in a university. 
 The progressive depletion in physician-
scientists has created an increasing
number of excellent academic opportu-
nities for Ph.D. scientists to be “first–
class citizens” in outstanding clinical
departments where they work “with”
rather than “for” physicians.
 Bridging the gap between advances in
biology and disease is the greatest chal-
lenge facing academic medicine today.
Training basic scientists in pathophysi-
ology is only one mechanism for bridging
this gap and does not replace efforts 
to increase the number of well-trained
physician-scientists and M.D.-Ph.D.
graduates. 
The Program involves a one-semester
course for 15 students that meets twice weekly
for 90 minutes. The clinical-pathologic and
basic mechanisms of the 20 major diseases of
man are considered. During the course, stu-
dents see patients, handle pathology speci-
mens, and become informed about every
major diagnostic and therapeutic facility in a
modern hospital.
From the results of an outcome survey com-
pleted by 182 students and fellows who have
taken the pathobiology course, 78 have com-
pleted postdoctoral fellowships. Of these, all
but 2 have a position in industry or academia,
and 33 have positions in biotechnical and
pharmaceutical companies, where they are
engaged in research that affects human
health. Twenty-seven have tenure track posi-
tions in basic science departments in excel-
lent institutions, and most have obtained grant
support. It is of considerable interest that the
remaining 22 individuals hold tenure track
positions in six clinical departments in different
medical schools throughout the country.
In addition to student and fellow outcome
results, various other evidence reveals the 
Program’s success. For example, substantial
interest has been expressed by more than 
50 institutions to replicate the Program. The
Lucille P. Markey Charitable Trust supported
nine such centers in 1997. A number of foun-
dations, NIH, and the National Academy of
“Much is known, but
unfortunately in 
different heads.”
Werner Kollath
Sciences have developed an interest in further
evaluating the theory that Ph.D. students and
fellows have an important role in bridging
advancements in basic sciences with medicine.
Arias believes that it is important to “demys-
tify medicine,” saying that “it is far easier to
teach basic pathophysiology to bright Ph.D.
students than to take last year’s chief medical
residents and turn them into bench scientists.” 
Graduate Training in 
Clinical Investigation
N. Franklin Adkinson, Jr., Physician-in-Charge
at the Johns Hopkins University Asthma and
Allergy Clinics, described a graduate training
program in clinical investigation, which serves
as one model of clinical research training. The
first of its kind in the United States, the pro-
gram was created in 1992 to address the
growing national concern over the shortage of
academic clinical investigators by training
clinical fellows to be more effective clinical 
scientists. 
Participants in the program acquire the
necessary skills to design and conduct clinical
investigations into emerging medical treat-
ments and technologies, new diagnostic tech-
niques, and new approaches to the study of
pathophysiology.
The usual career track is a four-year pro-
gram, which leads to both clinical board eligi-
bility in a medical discipline and a Ph.D. in
clinical investigation. One full year of didactic
instruction is ordinarily taken after an initial
clinical year in a medical or surgical specialty,
providing the scientific grounding for subse-
quent original research. Faculty from the pro-
gram and a preceptor from the fellow’s home
division or department jointly mentor this
research effort.
Fellows already enrolled in a clinical fellow-
ship program at Johns Hopkins may apply to
enter the program during their last year of clin-
ical training. Program fellows normally receive
tuition and stipend support consistent with the
usual level of postdoctoral support for their
clinical specialties.
Funding for students usually comes from a
variety of sources. Stipends and tuition can 
be provided from some NIH training grants 
or from other external training funds. Some
departments have used internal funds to sup-
port students or have obtained special fellow-
ships from pharmaceutical companies, said
Adkinson. Many career development awards
are suitable sources of support, but they may
be difficult to obtain before completing the first
year of the program. Adkinson reported that
one of the program’s greatest challenges has
been gathering sufficient financial support 
for what is essentially an interdisciplinary 
program. In addition, many students cannot
continue with the program because of the
pressures of indebtedness. Adkinson believes
that there is a vital role for public-private part-
nerships in addressing this very real concern.
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Arias believes that it is important to “demystify
medicine,” saying that “it is far easier to teach
basic pathophysiology to bright Ph.D. students than
to take last year’s chief medical residents and turn
them into bench scientists.”
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Wanted: Team Builders
In addition to the knowledge base required of
future clinical investigators, J. Claude Bennett,
President and Chief Operating Officer of
BioCryst Pharmaceuticals, said that post-
genomic medicine will need team builders.
Because molecular biology and clinical 
medicine are converging, said Bennett, drug
developers are desperately seeking highly
trained individuals who are conversant in
bench and bedside science. This is a big
challenge, he acknowledged, because the
requirements in basic science and clinical
training are greater than ever before.
“Being in the pharmaceutical industry, I 
see the real need for clinical scientists,” 
said Bennett. “But we can’t just wait for it to
happen. We have to be proactive. Formal 
programs are a necessity.”
Bennett mentioned that the pharmaceu-
tical industry spends $20 billion to $25 billion 
annually on research, of which 10 to 12 per-
cent is for basic discovery. Yet, all the drugs
currently on the market are probably related to
500 molecular targets. With the Human Genome
Project, there may be 10,000 good targets for
drug development. “We need to efficiently and
quickly explore the therapeutic opportunities
provided by those data,” he added.
Clinical scientists must have the necessary
knowledge base to use modern-day tools,
such as understanding molecular concepts,
how to use databases, and pharmacokinetics.
American Heart Association:
A Track Record of Supporting Promising New Scientists
Without sufficient funding during their early training, many talented young people
may be unable to pursue careers in academic medicine or the biological sciences.
Helping to develop promising young scientists is a priority of the American Heart
Association, which offers, through many of its affiliates, postdoctoral fellowships to
provide beginning researchers with essential research experience under the guidance
of a mentor. Other affiliate and national programs targeted at scientists in their first
faculty positions facilitate the move from a mentor’s research program to a fully
independent research effort.
Association Affiliate Research Programs are critical to new investigators. Most 
affiliates offer programs aimed at investigators who need postdoctoral training or 
initial project support before they can successfully compete for national awards, and
affiliate research committees—because of their familiarity with local universities,
medical schools and hospitals—have a unique opportunity to cultivate the research
potential of less experienced scientists.
National research programs focus on bridging the time between the postdoctoral
fellowship and the time when a beginning investigator is prepared to independently
compete for federal research funds. Scientist development awards and assistance 
for newly established investigators provide assistance to individuals beginning with
their first faculty position and continuing through the next 9 to 13 years, while also
supporting important research projects.
“Medical students are not being taught these
skills,” said Bennett. “There have to be mech-
anisms to provide these proficiencies to indi-
viduals who have a knowledge of human
biology.”
Efforts of Private Funders to
Support the Development of
Clinical Investigators
Private philanthropies, particularly voluntary
health agencies with a disease focus, histori-
cally have played a significant role in filling the
gap between the rate of advance in research
and the translation of new knowledge into 
therapies for human disease. Importantly, the
private sector can search for the right niche
and experiment with innovative approaches.
Private funders can use their funds to en-
courage beginning investigators to enter a
research area critical to the agency’s mission
or encourage midcareer investigators to
change course in their direction. 
For example, the Leukemia & Lymphoma
Society provides support for individuals pur-
suing careers in basic, clinical, or translational
research in leukemia, lymphoma, Hodgkin's
disease, and myeloma. Likewise, the Cancer
Research Fund of the Damon Runyon-Walter
Winchell Foundation is a nonprofit organiza-
tion dedicated to advancing cancer research.
Sometimes the bequest of a foundation’s
founder requires that the organization spend
its money in a particular area of research. The
Doris Duke Charitable Foundation is one such
organization.
Foundations can target areas that are tradi-
tionally underfunded. The Robert Wood John-
son Foundation, for example, has supported
development of clinical investigators for 
28 years, but has “built the fields that we feel
have been neglected that could improve the
health of the population,” said Lewis Sandy,
the Foundation’s Executive Vice President.
Organizations have used a variety of
approaches to support training and have
developed new models in recent years as
needs have changed, including postdoctoral
support, early career awards, and midcareer
awards. Most are focused on the physician
seeking a career in clinical research.
Postdoctoral support is a common mecha-
nism employed by many organizations. It is
typically seen as a traditional approach to 
providing stable support for beginning inves-
tigators to establish their laboratories. 
This type of support has been a focus of the
Damon Runyon-Walter Winchell Foundation
since 1946, reported Sarah Caddick, Director
of Award Programs for the Foundation’s 
Cancer Research Fund. It encourages the
nation’s most promising young investigators to
pursue careers in cancer research by funding
initial postdoctoral fellowships and Damon
Runyon Scholar Awards. The Damon Runyon
Scholar Award was established to support the
development of outstanding biomedical and
biochemical scientists as independent inves-
tigators in the cancer field by ensuring the 
continuity of their research productivity at the
critical transition from research training to first
faculty position.
Similarly, the Leukemia & Lymphoma Society
awards fellowships to promising investigators
with less than two years of postdoctoral
research training at the time of review. Fellows
are encouraged to embark on an academic
career involving clinical or fundamental re-
search in or related to leukemia, lymphoma,
Hodgkin’s disease, and myeloma. Fellowships
are $33,250 per year for three years. 
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Importantly, the private sector 
can search for the right niche 
and experiment with innovative
approaches.
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Private philanthropy also provides support
for physicians who want to be trained in
research. Since 1972, the Robert Wood John-
son Foundation’s Clinical Scholars Program
has provided a two-year fellowship for phy-
sicians interested in broad nonbiological
aspects of health and health care, such as 
epidemiology, health economics, ethics, and
health services research. Fellowships are
available at seven sites around the country
that also receive support for institutional infra-
structure and administration.
Elaine Gallin, Program Director for Medical
Research at the Doris Duke Charitable Foun-
dation, provided an example of midcareer
awards for clinical investigators. The Doris
Duke Distinguished Scientist Award targets
physician-scientists who are midcareer level
(associate level or full professor for no 
more than five years). The Award provides 
Doris Duke Charitable Foundation:
Targeting Clinical Training in Specific Disease Areas
The Clinical Scientist Award Program of the Doris Duke Charitable Foundation 
supports new investigators at the Assistant Professor level as they begin their careers
as independent clinical researchers. The program is limited to the development of
researchers in the areas of heart disease, AIDS, cancer, and sickle-cell anemia and
other blood disorders. 
The Foundation, which was formed in 1996, is specifically interested in 
 Studies on the etiology and pathogenesis of these diseases in man. 
 Therapeutic interventions. 
 Clinical trials. 
 Disease control research that investigates how scientifically obtained information
on prevention, early detection, and early diagnosis can be efficiently applied. 
 Epidemiological studies.
 Health outcomes research that either attempts to systematically determine the
risk/benefits and costs of various medical practices or attempts to utilize these
results in defining more effective medical practice guidelines. 
Candidates must have received an M.D. or equivalent degree from an accredited
institution within the past 10 years, must have completed 2 or more years of clinical
training and 2 years of postdoctoral experience, and must hold a full-time university
faculty appointment. 
Each three- to five-year award is for $100,000 per year. Should the applicant
require additional training in order to meet the Foundation’s educational demands,
an additional $25,000 will be awarded for six months of formal course work in the
areas of bioethics, protection of human subjects, informed consent, study design,
clinical trial record-keeping, quality assurance and control, and biostatistics.
stable research funding for investigators con-
ducting translational research—five years at
$600,000 per year.
Relieving Medical 
School Debt
“One in four medical school graduates has
over $100,000 in debt after completing his 
or her degree,” said Caddick of the Damon
Runyon-Walter Winchell Foundation. “In this
age of endless opportunity,” she remarked,
“the Cancer Research Fund is delighted to
announce a new program to help rescue an
endangered species—physicians willing to
devote their careers to the development and
application of new diagnostic approaches and
therapeutic strategies for cancer and cancer
prevention through clinical investigation.” The
Fund’s Clinical Investigator Award is ear-
marked for young physicians willing to commit
themselves to substantive and innovative 
clinical research; the Award bridges the gap
between the research laboratory and patient
care.
The Cancer Research Fund created the
program because of its belief that although
there has never been a more promising time
for clinical cancer research, fewer young
physicians are entering this area of investiga-
tion every year. Often, a major deterrent to
physicians making a commitment to clinical
investigation is their need to address major
debts that they acquired during medical
training.
The Fund’s new Award offers solutions to
this reality. The awardee and his or her senior
mentor receive financial support for up to five
years, as well as assistance for certain
research costs, such as the purchase of
equipment. Upon successful completion of
the Clinical Investigator Award program, the
Fund will also retire up to $100,000 of any
medical school debt still owed by the
awardee.
Applicants may apply during the final year
of their subspecialty training or within the first
two years of their junior faculty appointment.
Each applicant must be nominated by his or
her mentor and institution, and the institution 
is expected to guarantee the allocation of suf-
ficient research and office space to ensure the
proper start-up of the awardee. In addition, the
institution must provide the difference in salary
between the amount allocated by the Award
and the level appropriate for the position the
applicant holds at that institution.
The applicant is required to apply in con-
junction with a mentor who is established in
the field of clinical translational cancer
research or cancer prevention and epidemiol-
ogy and who can provide the critical guidance
needed during the Award period. The mentor
will receive partial salary support to be used
specifically to foster the education of the
awardee. A letter of commitment from the in-
stitution is required defining the position that
the applicant will occupy and outlining how 
the institution will enable the mentor to commit
a sufficient amount of time to the applicant’s
training and development.
Caddick estimates that the cost to the Fund
of a single award package is $1,125,000. She
reported that her phone has “been ringing off
the hook since the program was announced in
November 1999.”
An Alternative to the Career
Ladder Approach
Ray Vento, Assistant Vice President for Scien-
tific Program Administration, American Lung
Association, noted that his association, which
is the oldest voluntary health agency in the
country, must constantly compete with other
similar groups for support. The American 
Lung Association is a fundraising organization
rather than an endowed organization, and as
such it must balance national goals with local
programs. In addition, it spends most of its
funds every year. Supporting the academic
enterprise is not a primary goal.
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The Association has supported investigator-
initiated research since 1915. In 1980, it
switched to the “career ladder approach,”
said Vento, a strategy that was aimed at bring-
ing young people into pulmonary medicine
and allowing them to establish their independ-
ence. Other modifications were made in the
program in the ensuing years, changing some
of the “steps” of the ladder and placing it in
“different places,” added Vento. For example,
doctoral awards were granted, and efforts were
made to reach out to minority communities.
In the 1990s, it became clear that to raise
funds as well as to support research, the Asso-
ciation would have to change its strategy. In
1991, the Association Council voted to focus
on asthma, an approach that was important 
for advancing research but also for raising 
revenue. Since then, the Association has 
supported Asthma Research Centers that
combine research and training.
Public Sector Programs
How to revitalize the nation’s clinical research
enterprise has been a popular topic in recent
years. Since 1996, NIH has focused efforts 
on how to stem the precipitous decline in the
numbers of physician-scientists. NIH became
alarmed when between 1994 and 1997 the
number of first-time M.D. applicants plum-
meted 31 percent, from 838 to 575 appli-
cants. With only a 22 percent success rate in
1997 among M.D. applicants, only 126 M.D.s
served as first-time principal investigators 
on NIH research project grants. NIH statistics
showed a similar situation among M.D. post-
doctoral trainees supported by NIH through
individual fellowships and training grants. The
total number of M.D. postdoctoral trainees
plateaued at around 2,300 in the 1980s. But
between 1992 and 1997, that pool shrank to
1,261 such trainees.
In recent years, NIH has followed up on 
recommendations of the “Nathan Report”
through such efforts as establishing the K23
and K24 training awards for young and
midlevel career faculty and expanding the
number of medical students invited to take 
a year off from school to do research at 
NIH, reported Wendy Baldwin, NIH’s Deputy
Director for Extramural Research.
The purpose of the Mentored Patient-
Oriented Research Career Development
Award (K23) is to support the career develop-
ment of investigators who have made a com-
mitment to focus their research endeavors on
patient-oriented research, said Baldwin. This
mechanism provides support for three to five
years of supervised study and research for
clinically trained professionals who have the
potential to develop into productive clinical
investigators focusing on patient-oriented
research. In 1999, 139 awards were made.
With a view towards stabilizing clinical re-
search settings and preventing an interruption
in trainee mentoring, NIH has chosen to es-
tablish the Midcareer Investigator Award in
Patient-Oriented Research (K24). This award
is intended to relieve clinical investigators from
patient care duties and administrative respon-
sibilities in order to increase the opportunities
for midcareer clinicians to become well
grounded in patient-oriented research. In
1999, 81 such awards were made, reported
Baldwin.
Baldwin said that NIH supports loan repay-
ment programs in its intramural and extramural
programs and would like to increase the
amount of repayment awarded, a change that
would require new congressional legislation.
Development and Support
of Clinical Training on the
NIH Campus
NIH also has undertaken new clinical training
programs in its own clinical setting, reported
John Gallin, Director of the NIH Warren Grant
Magnuson Clinical Center. “Adequate training
and the infrastructure to support principal
investigators conducting clinical research are
essential to patient safety, protocol implemen-
tation, and quality assurance,” said Gallin,
“especially in interventional clinical trials.”
Indeed, even in natural history studies, such
infrastructure can only enhance the quality of
and access to the research by ensuring that
data are collected as required by the protocol
and are stored in a way that allows access to
the information without depending on any 
individual clinical researcher.
Training and education are first-order
requirements to ensure that clinical trial inves-
tigators have a consistent and complete
understanding of their responsibilities, added
Gallin. Clinical protocol design requires a
working knowledge of clinical trials method-
ology, biostatistics, and regulatory medicine.
Similarly, monitoring the trial during its execu-
tion involves many distinct responsibilities,
including reviewing each study subject’s
record to confirm his or her protocol eligibility,
reviewing each study subject’s record to
determine compliance with the protocol,
reporting adverse events to the Institutional
Review Board (IRB), determining necessary
changes in the protocol and the informed 
consent documents and submitting them as
protocol amendments to the IRB, monitoring
accrual to the study, and stopping the study
when the requirements of the study design
have been fulfilled or when it is clear that the
rate of accrual fails to meet expectations.
Under Gallin’s direction, all clinical principal
investigators on the NIH campus are required
to take an overview training course, or the
equivalent, on the roles and responsibilities of
clinical investigators.
In recent years, this approach has been
extended beyond the NIH campus and
beyond the M.D. The NIH-Duke Training Pro-
gram in Clinical Research leads to a Master 
of Health Sciences in Clinical Research, a 
professional degree awarded by the Duke
University School of Medicine. There is also a
nondegree option for qualified students who
want to pursue specific areas of interest. The
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Warren Grant Magnuson Clinical
Center, National Institutes of
Health: Introduction to the 
Principles and Practice of 
Clinical Research
Introduction to the Principles and 
Practice of Clinical Research is a study
curriculum on how to effectively conduct
clinical research that was established 
at the Warren G. Magnuson Clinical 
Center—the clinical research hospital 
of NIH. This curriculum is designed to
teach researchers how to design a 
clinical trial. It covers epidemiologic
methods and focuses on study design 
and development, protocol preparation,
patient monitoring, quality assurance,
and regulatory issues and also includes
data management and legal and ethical
issues, including protection of human
subjects. 
Course objectives are to become 
familiar with the basic epidemiologic
methods involved in clinical research; 
to be able to discuss the principles
involved in the ethics of clinical
research, the legal issues involved in
clinical research, and the regulations
involved in human subjects research,
including the role of IRBs in clinical
research; to become familiar with the
principles and issues involved in moni-
toring patient-oriented research; and 
to be able to discuss the infrastructure
required in performing clinical research
and to understand the steps involved in
developing and funding research studies.
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Duke program, established in 1986, is one of
the nation’s first training programs in clinical
research. This collaboration between the NIH
Warren G. Magnuson Clinical Center and the
Duke University School of Medicine marks the
first time that the program has been made
available for long-distance learners, said
Gallin. In addition, students at NIH can attend
classes at Duke by way of video conferencing.
The curriculum covers the principles of clinical
research, including research design, statistical
analysis, health economics, research ethics,
and research management. The availability of
teleconferencing and telemedicine provides
unprecedented opportunities for reaching out
to clinical centers that have been “islands,”
said Gallin.
Finally, Gallin mentioned a program offered
to medical students between their third and
fourth year of training. Like the Howard
Hughes Medical Institute-NIH Cloister Program,
students spend a year working with a research
mentor on campus to gain exposure to labo-
ratory investigation. The program is funded 
by Pfizer, Inc., which committed $1.6 million
over two years to the National Foundation for
Biomedical Research to sponsor 16 clinical
research training fellows at NIH. 
The program focuses on third-year medical
and dental students and brings them to the
NIH campus for a year of didactic and practi-
cal hands-on experience. The students are
selected in a competitive process by an advi-
sory committee of experts in clinical research.
Students work in NIH laboratories and clinics
and are mentored by senior clinical investiga-
tors. They also take a core course in clinical
research and receive a stipend for living
expenses and other support.
The Medical Scientist 
Training Program
The NIH MSTP, administered by Bert Shapiro, 
supports the integrated medical and gradu-
ate research training that is required for the 
investigation of human diseases. It is widely
believed to be a model that works, as 85 per-
cent of the individuals who participate in the
Program remain actively involved in academic
medicine.
The MSTP assures highly selected trainees
a choice of a wide range of pertinent graduate
programs in the biological, chemical, and
physical sciences, which, when combined
with training in medicine, lead to the M.D.-
Ph.D. degree. Programs are encouraged to
provide a breadth of doctoral research training
opportunities consistent with individual institu-
tional strengths. In addition to the above dis-
ciplines, support of trainees in other disci-
plines, such as computer sciences, social and
behavioral sciences, economics, epidemiol-
ogy, public health, bioengineering, biostatis-
tics, and bioethics, is appropriate. According
to Shapiro, MSTP programs should be flexible
and adaptable in providing each trainee with
the appropriate background in the sciences
relevant to medicine, yet they should be suffi-
ciently rigorous to enable graduates to func-
tion independently in both basic research and
clinical investigation. In 1999, the Program
awarded $26 million to 40 participating insti-
tutions. This type of program provides “the 
perfect model” for collaboration between the
public sector and the private sector, com-
mented Shapiro, who added that despite the
success of the Program, the participating insti-
tutions are chronically underfunded. Clinical
research training is expensive, he concluded,
and public-private sector partnerships are
essential in bridging the gap.
Goals for Private Funders
There are many new and exciting opportunities
in clinical research that have been provided by
the genetic revolution and other scientific
advances. “We are seeing increasing demand
for clinical research as we enter into this 
much-heralded postgenomic era,” concluded
Richard Lifton. “But we have to overcome
enormous institutional challenges as the 
traditional streams of revenue are redirected 
or dry up.” Two major investment areas have
emerged to advance clinical research—
human capital and training programs. Both
require innovative approaches as we enter
the realm of molecular medicine.
Human Capital
1. The development of clinical scientists is
a good target for private support. How-
ever, as with training basic scientists, it 
is critically important to support young
clinical scientists, although other steps 
in the ladder also require attention.
Research experiences during medical
school, such as the Howard Hughes
Medical Institute-NIH Cloister Program
and the NIH-Pfizer Clinical Research
Training Program, are excellent exam-
ples of programs that support clinical
investigators early in their careers,
before receiving the doctorate.
2. The M.D.-Ph.D. is the most successful
model for the development of clinical 
scientists. This model should be sup-
ported by the private sector in order to
expand the current numbers of trainees
at currently funded sites or to develop
new programs at institutions that could
then become eligible for NIH support.
The NIH program currently supports only
six years of training, leaving institutions
to fill the gap for what is an eight-year
program.
3. Despite the predominance of the M.D.-
Ph.D. scientist, there are other essential
types of physician-scientists, and these
scientists require different types of 
support.
• Numerous new master’s-level pro-
grams are in development for clinical
research training. The private sector
can make a contribution by assisting
with tuition support.
• Ph.D.s, if trained in pathobiology or
other human disease constructs, can
provide an invaluable resource to the
clinical research team.
4. Transition support to assist individuals at
key points in their training and career
development, such as between thesis
work and the first independent faculty
position, can be essential to prevent
young scientists from leaving research.
In this respect, debt relief is crucial.
Because it is difficult for government
agencies to provide adequate funds in
this area, private philanthropy can make
a valuable contribution.
Training Programs
1. The development of multidisciplinary
and generic training programs in clinical
research is urgently needed, and the
collaboration of disease-oriented groups
to provide such support could make a
critical difference. Such a consortium
could provide funds for junior faculty and
graduate students as they make impor-
tant education and career transitions.
2. There are a number of possible models
for Ph.D. training for clinical research
that could be targets of private support.
3. The private sector could support inno-
vative mechanisms by which to develop
and support mentorship skills in new and
existing faculty.
4. Although a number of master’s-level 
programs for clinical research have 
been funded, innovation in training
approaches is needed to meet emerging
needs in academic and industrial 
science.
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American Association for the Advancement of Science
GrantsNet and NextWave
Ellis Rubinstein, Editor of Science magazine, traced the progress of the
American Association for the Advancement of Science Websites, GrantsNet
(www.grantsnet.org) and NextWave (www.nextwave.org) (developed
through collaborations with the Howard Hughes Medical Institute and 
the Burroughs Wellcome Fund), both of which represent unusual partner-
ships for a science magazine that has been produced as a sole venture 
for most of its 120 years. GrantsNet, part of the Association’s NextWave 
Website, is a free, searchable online database of funding options for 
biomedical scientists in the training phases of their careers. The site was
funded by a three-year, $900,000 grant from the Howard Hughes Medical
Institute and has been in operation for two years. Currently, it has 250 par-
ticipating organizations, 52,000 registered users, and 604 programs in 
its database.
NextWave, established through support from the Burroughs Wellcome
Fund, is the parent of GrantsNet. In operation since 1995, NextWave targets
graduate and postdoctoral students and provides career advice and the
opportunity for online exchanges among young scientists and between
young scientists and experts. The site currently features a career develop-
ment center that was initiated through a grant from the Burroughs Wellcome
Fund and the Howard Hughes Medical Institute, and, in addition to support
through a number of professional societies and government agencies,
NextWave has a number of international collaborators.
Current plans include the redesign of the GrantsNet homepage, the
development of a database for undergraduates in search of research 
opportunities, and expanded international scientific collaborations. Both
GrantsNet and NextWave, said Mr. Rubinstein, demonstrate what can be
accomplished by combining Web-based technologies for electronic grants-
making with effective partnerships with organizations that have been at the
forefront of the use of these technologies.
Howard Hughes Medical Institute
Graduate Competition System
Joseph Perpich, Vice President for Grants and Special Programs, focused
on the online application system the Institute has developed for its graduate
fellowship programs—the Graduate Competition System. Prospective appli-
cants access the system by going to the graduate program’s home page,
where they are linked to program announcements, eligibility criteria, appli-
cation forms, and instructions and tips. An applicant registers and is given 
a personal identification number (PIN) and password for the application, 
as well as PINs and passwords for third parties, such as mentors and 
references, who also use the Web system to submit information.
Several features of the system are particularly useful. An application
checklist, for example, tells applicants which third-party materials—
transcripts, references, mentor materials—have been received by the Insti-
tute. This relieves staff from having to field many telephone calls and e-mails
from applicants. Data entry is handled in two ways: Some fields use free-
form entry (for example, current position), while others are selected from
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standardized lists (for example, institutional affiliation,
research field). Essay material on the application is
handled by uploading a Rich Text Format file.
Applicants and mentors must complete the forms
online and submit them to the Institute via the Web.
After the application is submitted, the data are trans-
ferred to the non-Web component of the Graduate
Competition System for management during the review
and award process. For most Institute grants pro-
grams, the review process is handled almost entirely
online. The Graduate Competition System is viewed by
the Institute as "shareware" that can be made available
to other funders at no cost (although funders would have
to assume costs associated with any adaptations). 
In addition, the Institute has undertaken significant
standardization efforts. As a result, staff can analyze
programs in terms of an array of variables and can also
conduct a variety of cross-program analyses (for exam-
ple, educational origins of graduate fellows, number of
under-represented minorities participating in Institute-
supported programs).
American Cancer Society 
Foundation Commons
The American Cancer Society has established the
Foundation Commons Consortium, which provides a
shared online application system for voluntary health
agencies (www.foundationcommons.org). The Society
coordinates this system, explained Dr. T.J. Koerner,
Director of Research Information Management, with a
number of other voluntary health agencies, including
the Alzheimer’s Association, the Cystic Fibrosis Foun-
dation, and the Juvenile Diabetes Foundation. Science-
Wise, the vendor that developed the system, is
experienced with e-commerce applications and grant
processes and serves as the point of contact for the
member organizations, each of which has different
needs for data and services. 
At this time, Foundation Commons is not sharing
grant results and is instead focusing on the application
process. The system does not attempt to alter internal
institutional review processes, but rather frees appli-
cants from the burden of updating multiple profiles by
creating one common profile for each applicant. After
selecting the consortium member to which they wish to
apply, users register by filling out and submitting a per-
sonal profile information form. They then download the
application in Portable Document Format (PDF), com-
plete the application offline, and submit the application
in electronic and paper format per the consortium
member’s instructions. The information goes to the
Foundation Commons’ central database and is trans-
ferred electronically to the consortium member’s own
system. Because the technology allows the use of both
specialized and standardized fields, data standardiza-
tion is used where it makes sense. For example,
through this system, an application can be submitted
to any organization that uses the federal government
194 Data Set standard.
To save completed forms in PDF, applicants are
required to have access to Adobe Acrobat Exchange
4.0, which, unlike Adobe Acrobat Reader, is not free,
although this is the system’s only limiting technological
requirement. In discussion, participants noted the lack
of inexpensive, nonproprietary software as a common
obstacle to use and standardization of online applica-
tion systems and emphasized the need to think care-
fully about how the proliferation and use of these
systems may affect those who are submitting research
applications, where overhead and indirect costs are
involved.
National Science Foundation
FastLane Project
The National Science Foundation developed this 
Web-based system for the submission and review of
grant proposals (www.fastlane.nsf.gov) and currently
receives approximately 22,000 applications a year
through the site. In addition, approximately 80,000
reviews and 99 percent of project reports have been
received through FastLane. Carolyn Miller, Branch
Chief, External Systems, stressed the importance of
having appropriate external and internal functions in
place in order for this kind of system to work. External
functions that need to be in place at agencies include
proposal preparation and submission; reference
preparation and submission; proposal review; panel
travel; and organizational management. The Founda-
tion provides a number of internal functions to its staff
through FastLane, such as an electronic jacket that
includes all available information; a review manage-
ment utility that allows staff to manage reviewers and
panels; functions that provide the ability to generate
reports and track progress; and the ability to transfer
information to and from internal processing systems. 
From the perspective of proposal processing, an
important advantage to this system is that parts of the
review process can be initiated before the actual
review begins. Overall, Ms. Miller noted, processes
that involve mainly straightforward data transactions
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have worked well; in the area of awards management,
for example, the system has significantly reduced the
time it takes to apply and receive approval for a no-cost
extension. The most complicated process to imple-
ment electronically has been proposal preparation.  
FastLane’s vision for the future, one that will help
meet the challenges of Internet accessibility and server
performance (especially when deadlines are involved),
is one of a connection-free process for all FastLane
functions. Through a connection-free process, for
example, reviewers can download a function and work
off-line and then submit their work either through e-mail
or the Web. Another important challenge is the need for
software that can be used with any word processor and
that can support scientific images. Currently, FastLane
uses PDF files for documents that include scientific
illustrations; however, a promising competitor, called
GoScript 6.0, is now available and is supported on
Unix, PC, and Mac platforms. 
National Institutes of Health
NIH Electronic Research Administration 
Commons Project (NIH Commons)
George Stone, Chief, Commons, Extramural Inven-
tions, and Technology Resources Branch at the
National Institutes of Health (NIH), noted that the fed-
eral government’s mandate to reduce the amount of
paperwork within the next 18 months will significantly
affect how the government processes applications and
awards. Through its NIH Electronic Research Adminis-
tration Commons (www-commons.cit.nih.gov), NIH is
working to accomplish this transition from paper to
electronic processes throughout the grants lifecycle
and to make its systems more applicable and less pro-
prietary in a thoughtful way, despite the speed with
which the new technology is advancing and the 
challenges that are presented in replacing the 30- 
to 50-year-old legacy systems. The NIH Commons 
is implementing Internet processes for information
exchange through two main strategies: The first is to
disseminate unrestricted information, which does not
require a user log-in. The second is to provide for the
exchange of confidential information, which requires
registration and log-in. 
NIH Commons uses a system of controlled deploy-
ment in which the system is first offered to a small 
number of organizations that have expressed interest
in it, and then, after the system is refined based on
feedback from these organizations, it is offered more
widely. Currently about 125 schools are using the sys-
tem, which is now considered to be in expanded
deployment. "To be successful, we must take into
account the diversity of the grantee population and
accommodate the differences through a combination
of structure and flexibility," remarked Dr. Stone, who
added that NIH Commons employs a common stan-
dard, the 194 Data Set, which serves as a common
data dictionary that is used by both the government
and the private sector. 
NIH Commons supports an online electronic pro-
filing system and provides a secure and confidential
environment within which users can conduct their 
business. Because the goal is to be flexible in the use
of technological approaches, NIH Commons tries to
avoid the use of proprietary software, such as PDF;
however, no nonproprietary method currently is avail-
able that can be used for the scientific illustrations that
are often included in applications. NIH Commons will
support Extensible Markup Language technology,
which, once a tool is available to support it, could 
render PDF obsolete. At this time, the system adheres
to standard syntax formats, such as Interactive 
Web, Electronic Data Interchange, HyperText Markup 
Language, and Adobe forms filling. 
Recent developments at NIH Commons include the
use of e-Snap for the submission of noncompeting
application data into a streamlined awards process
and the use of e-Fellowships for the preparation and
submission of fellowship applications via Interactive
Web. X-train, for electronic trainee activities, is a secure
interactive Website for statement of appointments and
termination notices of extramural trainees. NIH Com-
mons also supports a profiling system and a system for
checking the status of pending applications. In addi-
tion, an application viewer is available that allows an
applicant to see how the application will look before
submitting it.
Discussion focused on whether the Web could
make it easier for those who are not serious applicants
to apply for awards and in the process disrupt grants-
making sites. Dr. Stone noted that because NIH Com-
mons uses a strong authorization protocol, such use
would be unlikely. Registration includes a faxed author-
izing signature, and all information that is provided by
the applicant is validated. In addition, affiliation is
required in order to submit an application, except for
fellowship applications, which must be submitted by a
sponsor in order to be accepted.
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Monday, February 14, 2000
Welcome and Opening Remarks
 Thomas R. Cech, Ph.D., President, Howard Hughes Medical Institute
 Enriqueta Bond, Ph.D., Burroughs Wellcome Fund
 John Stevens, M.D., American Cancer Society
Forum on the New World of Electronic Grantsmaking
Moderator: Joseph G. Perpich, M.D., J.D., Howard Hughes Medical Institute
 Ellis Rubinstein, “GrantsNet,” “NextWave,” Science magazine
 T. J. Koerner, Ph.D., “Foundation Commons,” American Cancer Society
 Carolyn Miller, “FastLane,” National Science Foundation
 George Stone, Ph.D., “NIH Commons,” National Institutes of Health
Tuesday, February 15, 2000
Basic Biomedical Research Training
Welcome
Thomas R. Cech, Ph.D., President, Howard Hughes Medical Institute
Perspectives on the Future of Basic Biomedical Research
David Botstein, Ph.D., Stanford University
Competencies Required of the Next Generation of Basic Scientists
Thomas R. Cech, Ph.D., Howard Hughes Medical Institute
Challenges and Opportunities in Training Basic Biomedical Scientists
Moderator: Thomas R. Cech, Ph.D., Howard Hughes Medical Institute
 Stephen Burley, M.D., D.Phil., Howard Hughes Medical Institute, 
Rockefeller University
 Nicholas R. Cozzarelli, Ph.D., University of California-Berkeley
 Freeman A. Hrabowski, Ph.D., University of Maryland, Baltimore County
 David Botstein, Ph.D., Stanford University
Current Programs and Plans of Private Funders
Moderator: Donella Wilson, Ph.D., American Cancer Society
 Jaleh Daie, Ph.D., The David and Lucile Packard Foundation
 Susan Barnett, M.A., American Heart Association
 Robert Goldstein, M.D., Ph.D., Juvenile Diabetes Foundation
 Maria Pellegrini, Ph.D., W.M. Keck Foundation
Current Programs and Plans of Federal Funders
Moderator: Michael Teitelbaum, Ph.D., Alfred P. Sloan Foundation
 Marvin Cassman, Ph.D., National Institute of General Medical Sciences
 Mary Clutter, Ph.D., National Science Foundation
 Elke Jordan, Ph.D., National Human Genome Research Institute
 John Ruffin, Ph.D., National Institutes of Health
Summary of the Day
David Botstein, Ph.D., Stanford University
Evening Speaker
Ethical Issues Associated with Future Biomedical Research
R. Alta Charo, J.D., University of Wisconsin-Madison
Wednesday, February 16, 2000
Clinical Research Training 
Welcome
Enriqueta Bond, Ph.D., President, Burroughs Wellcome Fund
The Future of Clinical Research
Richard P. Lifton, M.D., Ph.D., Howard Hughes Medical Institute, 
Yale University School of Medicine
Challenges and Opportunities in Training Clinical Researchers
Moderator: John Stevens, M.D., American Cancer Society
 Edward Holmes, M.D., Duke University Medical Center
 Irwin M. Arias, M.D., Tufts University
 N. Franklin Adkinson, Jr., M.D., Johns Hopkins University
 J. Claude Bennett, M.D., BioCryst Pharmaceuticals
Current Programs and Plans of Private Funders
Moderator: Lewis G. Sandy, M.D., Robert Wood Johnson Foundation
 Elaine Gallin, Ph.D., Doris Duke Charitable Foundation
 Sarah Caddick, Ph.D., Damon Runyon-Walter Winchell Foundation 
 Marshall Lichtman, M.D., The Leukemia & Lymphoma Society
 Ray Vento, American Lung Association
Current Programs and Plans of Federal Funders of Research
Moderator: Myrl Weinberg, CAE, National Health Council
 John I. Gallin, M.D., Warren G. Magnuson Clinical Center 
 Bert Shapiro, Ph.D., National Institute of General Medical Sciences
 Wendy Baldwin, Ph.D., National Institutes of Health 
Summary of the Day
Richard P. Lifton, M.D., Ph.D., Howard Hughes Medical Institute, 
Yale University School of Medicine
Closing Remarks and Adjournment
John Stevens, M.D., American Cancer Society
Enriqueta Bond, Ph.D., Burroughs Wellcome Fund
Thomas R. Cech, Ph.D., Howard Hughes Medical Institute
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